Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.
Christian Cottingham-Endter has quite a few chronic conditions that make staying active and eating right a challenge. One of them is psoriatic arthritis. But thanks ...
Yonhap News Agency on MSN2d
Celltrion launches autoimmune disease treatment in U.S.Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
Overactive bladder (OAB) is associated with arthritis, with a positive association seen after adjustment for all covariates.
Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.
US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...
MedPage Today on MSN5d
TYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisThe TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback